GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sun Biomedical Ltd (ASX:SBN) » Definitions » YoY EBITDA Growth

Sun Biomedical (ASX:SBN) YoY EBITDA Growth : 0.00% (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Sun Biomedical YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Sun Biomedical's YoY EBITDA Growth for the quarter that ended in Dec. 2023 was 0.00%.

Sun Biomedical's EBITDA per Share for the six months ended in Dec. 2023 was A$0.00.

Sun Biomedical YoY EBITDA Growth Historical Data

The historical data trend for Sun Biomedical's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sun Biomedical YoY EBITDA Growth Chart

Sun Biomedical Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Sun Biomedical Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Sun Biomedical YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Sun Biomedical's YoY EBITDA Growth for the fiscal year that ended in Jun. 2023 is calculated as:

YoY EBITDA Growth (A: Jun. 2023 )
=(EBITDA per Share (A: Jun. 2023 )-EBITDA per Share (A: Jun. 2022 ))/ | EBITDA per Share (A: Jun. 2022 ) |
=(-)/ | |
=N/A %

Sun Biomedical's YoY EBITDA Growth for the quarter that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (Q: Dec. 2023 )
=(EBITDA per Share (Q: Dec. 2023 )-EBITDA per Share (Q: Dec. 2022 )) / | EBITDA per Share (Q: Dec. 2022 )) |
=(-)/ | |
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sun Biomedical YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Sun Biomedical's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Sun Biomedical (ASX:SBN) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sun Biomedical Ltd (ASX:SBN) » Definitions » YoY EBITDA Growth
Comparable Companies
ASX:PIQ ASX:RCE ASX:RAC ASX:ALA ASX:PAA ASX:PAR ASX:OCC ASX:ACW ASX:AGN ASX:SPL OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
DXB:Australia
Address
425 Smith Street, Fitzroy, VIC, AUS, 3065
Website
https://www.dimerix.com
Dimerix Ltd is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs. The company is developing five product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for COVID-19 pneumonia patients in ICU; DMX-200 for respiratory complications in Covid-19 patients; and DMX-700 for COPD; as well as the proprietary ReceptorHIT assay technology.

Sun Biomedical (ASX:SBN) Headlines

No Headlines